Evofem Biosciences to Present at Emerging Growth Conference
Evofem Biosciences (OTCQB: EVFM) has announced its upcoming participation in the Emerging Growth Conference on Thursday, April 17, 2025. The company's management team will deliver a presentation from 10:50 鈥� 11:20 am ET (7:50 鈥� 8:20 am PT).
The event will feature a live webcast accessible through the company's investor relations website. Following the presentation, there will be a Q&A session open to attendees. Investors, analysts, and investment advisors are encouraged to register early and submit questions in advance to [email protected].
The presentation will be available for viewing both live and as an archived recording through EmergingGrowth.com and the Emerging Growth YouTube Channel. Once available, an archive link will be added to Evofem's investor relations website.
Evofem Biosciences (OTCQB: EVFM) ha annunciato la sua prossima partecipazione alla Emerging Growth Conference che si terr脿 gioved矛 17 aprile 2025. Il team di gestione dell'azienda presenter脿 un intervento dalle 10:50 alle 11:20 ET (7:50 鈥� 8:20 PT).
L'evento includer脿 una diretta web accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda. Dopo la presentazione, ci sar脿 una sessione di domande e risposte aperta ai partecipanti. Gli investitori, gli analisti e i consulenti finanziari sono invitati a registrarsi in anticipo e a inviare domande in anticipo a [email protected].
La presentazione sar脿 disponibile per la visione sia in diretta che come registrazione archiviata tramite EmergingGrowth.com e il canale YouTube di Emerging Growth. Una volta disponibile, un link all'archivio sar脿 aggiunto al sito web delle relazioni con gli investitori di Evofem.
Evofem Biosciences (OTCQB: EVFM) ha anunciado su pr贸xima participaci贸n en la Emerging Growth Conference el jueves 17 de abril de 2025. El equipo directivo de la compa帽铆a realizar谩 una presentaci贸n de 10:50 a 11:20 am ET (7:50 a 8:20 am PT).
El evento contar谩 con una transmisi贸n en vivo accesible a trav茅s del sitio web de relaciones con inversores de la compa帽铆a. Despu茅s de la presentaci贸n, habr谩 una sesi贸n de preguntas y respuestas abierta a los asistentes. Se anima a los inversores, analistas y asesores de inversiones a registrarse con anticipaci贸n y enviar preguntas previamente a [email protected].
La presentaci贸n estar谩 disponible para su visualizaci贸n tanto en vivo como en una grabaci贸n archivada a trav茅s de EmergingGrowth.com y el canal de YouTube de Emerging Growth. Una vez disponible, se a帽adir谩 un enlace al archivo en el sitio web de relaciones con inversores de Evofem.
Evofem Biosciences (OTCQB: EVFM)电� 2025雲� 4鞗� 17鞚� 氇╈殧鞚�鞐� 鞐措Μ电� Emerging Growth Conference鞐� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 瓴届榿歆� 韺�鞚� 鞓れ爠 10:50 鈥� 11:20 ET (鞓れ爠 7:50 鈥� 8:20 PT) 霃欖晥 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
鞚� 鞚措菠韸傅鐢 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戧芳頃� 靾� 鞛埖鐢 霛检澊敫� 鞗轨簮鞀ろ姼毳� 韽暔頃╇媹雼�. 氚滍憸 頉勳棎电� 彀胳劃鞛愲摛鞚� 鞙勴暅 歆堧 氚� 雼惦硛 靹胳厴鞚� 歆勴枆霅╇媹雼�. 韴瀽鞛�, 攵勳劃臧� 氚� 韴瀽 瓿犽霌れ潃 氙鸽Μ 霌彪頃橁碃 [email protected]鞙茧 歆堧鞚� 鞝滌稖頃� 瓴冹潉 甓岇灔頃╇媹雼�.
氚滍憸电� EmergingGrowth.com 氚� Emerging Growth YouTube 毂勲剱鞚� 韱淀暣 鞁れ嫓臧勳溂搿� 鞁滌箔 臧�電ロ晿氅�, 雲鬼檾霅� 鞛愲搿滊弰 鞝滉车霅╇媹雼�. 鞚挫毄 臧�電ロ暣歆�氅� Evofem鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐� 鞎勳勾鞚措笇 毵來伂臧� 於旉皜霅� 鞓堨爼鞛呺媹雼�.
Evofem Biosciences (OTCQB: EVFM) a annonc茅 sa prochaine participation 脿 la Emerging Growth Conference le jeudi 17 avril 2025. L'茅quipe de direction de l'entreprise fera une pr茅sentation de 10h50 脿 11h20 ET (7h50 脿 8h20 PT).
L'茅v茅nement comprendra un webinaire en direct accessible via le site web des relations investisseurs de l'entreprise. Apr猫s la pr茅sentation, une session de questions-r茅ponses sera ouverte aux participants. Les investisseurs, analystes et conseillers en investissement sont encourag茅s 脿 s'inscrire t么t et 脿 soumettre des questions 脿 l'avance 脿 [email protected].
La pr茅sentation sera disponible en direct et en tant qu'enregistrement archiv茅 via EmergingGrowth.com et la cha卯ne YouTube de Emerging Growth. Une fois disponible, un lien vers l'archive sera ajout茅 au site web des relations investisseurs d'Evofem.
Evofem Biosciences (OTCQB: EVFM) hat seine bevorstehende Teilnahme an der Emerging Growth Conference am Donnerstag, den 17. April 2025 angek眉ndigt. Das Management-Team des Unternehmens wird eine Pr盲sentation von 10:50 bis 11:20 Uhr ET (7:50 bis 8:20 Uhr PT) halten.
Die Veranstaltung wird einen Live-Webcast umfassen, der 眉ber die Investor-Relations-Website des Unternehmens zug盲nglich ist. Nach der Pr盲sentation wird es eine Frage- und Antwortsitzung f眉r die Teilnehmer geben. Investoren, Analysten und Anlageberater werden ermutigt, sich fr眉hzeitig zu registrieren und Fragen im Voraus an [email protected] zu senden.
Die Pr盲sentation wird sowohl live als auch als archivierte Aufnahme 眉ber EmergingGrowth.com und den Emerging Growth YouTube-Kanal verf眉gbar sein. Sobald sie verf眉gbar ist, wird ein Archivlink auf der Investor-Relations-Website von Evofem hinzugef眉gt.
- None.
- None.
Date:聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 | Thursday, April 17, 2025 |
Time:聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 | 10:50 鈥� 11:20 am ET (7:50 鈥� 8:20 am PT) |
Live webcast:聽 聽 聽 聽 聽 | or |
Following the presentation, the Company plans to open the floor for questions. Investors, analysts and investment advisors are encouraged to register early for the conference and to submit questions in advance 迟辞听蚕耻别蝉迟颈辞苍蝉蔼贰尘别谤驳颈苍驳骋谤辞飞迟丑.肠辞尘.
The webcast will be live and archived thereafter via EmergingGrowth.com and on the . A link to the archive will be added to the 聽on Evofem's investor relations website when available.
About Evofem Biosciences
is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.
is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. 聽
SOLOSEC庐 (secnidazole) 2g oral granules聽is a next generation 5-nitroimidazole drug FDA-approved oral antibiotic聽for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one oral dose.聽Evofem's commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the
To learn more, visit .
PHEXXI庐 and SOLOSEC庐 are registered trademarks of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
Contact
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775
View original content to download multimedia:
SOURCE Evofem Biosciences, Inc.
FAQ
When is Evofem Biosciences (EVFM) presenting at the Emerging Growth Conference?
How can investors watch EVFM's Emerging Growth Conference presentation?
Can investors ask questions during EVFM's Emerging Growth Conference presentation?
Will EVFM's Emerging Growth Conference presentation be available after the live event?
